
Annual report 2024
added 03-14-2026
argenx SE Market Cap 2011-2026 | ARGX
As of March 26, 2026 argenx SE has a market cap of $ 25 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap argenx SE
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 13.8 B | 11.3 B | 5.57 B | 3.82 B | 1.91 B | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.8 B | 1.91 B | 7.27 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 2.3 | -1.29 % | $ 3.01 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 220.9 | 2.49 % | $ 5 B | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 19.57 | 1.77 % | $ 915 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Phathom Pharmaceuticals
PHAT
|
986 M | $ 10.47 | 4.08 % | $ 763 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Pliant Therapeutics
PLRX
|
81.6 M | $ 1.31 | 2.34 % | $ 80.4 M | ||
|
PMV Pharmaceuticals
PMVP
|
85.6 M | $ 1.37 | -1.44 % | $ 72 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.33 | 0.76 % | $ 339 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 8.31 | 1.59 % | $ 111 M | ||
|
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 47.09 | 1.42 % | $ 4.23 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
5.58 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
277 M | $ 3.26 | 4.49 % | $ 251 M | ||
|
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | ||
|
ProQR Therapeutics N.V.
PRQR
|
68.7 M | $ 1.58 | 6.04 % | $ 99.5 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
116 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Palatin Technologies
PTN
|
83.7 K | $ 21.0 | 5.79 % | $ 19.5 M | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Pulmatrix
PULM
|
10.8 M | $ 2.12 | -1.4 % | $ 7.74 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.53 | 5.1 % | $ 868 M | ||
|
Homology Medicines
FIXX
|
76.3 M | - | 0.77 % | $ 53.4 M |